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introduction: The current methodology involving diagnosis of prostate cancer (PCa) 
relies on the pathology examination of prostate needle biopsies, a method with high false 
negative rates partly due to temporospatial, molecular, and morphological heterogeneity 
of prostate adenocarcinoma. It is postulated that molecular markers have a potential to 
assign diagnosis to a considerable portion of undetected prostate tumors. This study 
examines the genome-wide DNA methylation changes in PCa in search of genomic 
markers for the development of a diagnostic algorithm for PCa screening.
Methods: Archival PCa and normal tissues were assessed using genomic DNA methyl-
ation arrays. Differentially methylated sites and regions (DMRs) were used for functional 
assessment, gene-set enrichment and protein interaction analyses, and examination of 
transcription factor-binding patterns. Raw signal intensity data were used for identifi-
cation of recurrent copy number variations (CNVs). Non-redundant fully differentiating 
cytosine-phosphate-guanine sites (CpGs), which did not overlap CNV segments, were 
used in an L1 regularized logistic regression model (LASSO) to train a classification algo-
rithm. Validation of this algorithm was performed using a large external cohort of benign 
and tumor prostate arrays.
results: Approximately 6,000 probes and 600 genomic regions showed significant DNA 
methylation changes, primarily involving hypermethylation. Gene-set enrichment and 
protein interaction analyses found an overrepresentation of genes related to cell com-
munications, neurogenesis, and proliferation. Motif enrichment analysis demonstrated 
enrichment of tumor suppressor-binding sites nearby DMRs. Several of these regions 
were also found to contain copy number amplifications. Using four non-redundant fully 
differentiating CpGs, we trained a classification model with 100% accuracy in discrimi-
nating tumors from benign samples. Validation of this algorithm using an external cohort 
of 234 tumors and 92 benign samples yielded 96% sensitivity and 98% specificity. The 
model was found to be highly sensitive to detect metastatic lesions in bone, lymph node, 
and soft tissue, while being specific enough to differentiate the benign hyperplasia of 
prostate from tumor.
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conclusion: A considerable component of PCa DNA methylation profile represent driver 
events potentially established/maintained by disruption of tumor suppressor activity. As 
few as four CpGs from this profile can be used for screening of PCa.
Keywords: prostate cancer, Dna methylation, protein interaction, transcription factor binding, copy number 
variation, differentially methylated regions, machine learning, lassO
inTrODUcTiOn
Prostate cancer (PCa) is the most common malignancy in men, 
representing the third greatest cause of mortality in the general 
population after lung and colorectal cancer (1). Current screening 
protocols for PCa rely on digital rectal examination along with the 
evaluation of serum levels of prostate-specific antigen. If a tumor 
is suspected, trans-rectal, ultrasound-guided, prostate needle 
biopsies are conducted, followed by a histopathology examina-
tion. Major limitations of this approach include a relatively high 
false negative rate and the requirement for annual follow-ups and 
repeat sampling, an invasive approach with significant burden on 
patient health care and lifestyle (2). As such, a significant effort 
has been made to identify more accurate diagnostic and screen-
ing biomarkers for PCa, though to date this effort has been met 
with limited success in clinical application (3).
Among the markers that have gained interest in disease 
screening is DNA methylation, an epigenetic mechanism that 
includes modification of the fifth base of cytosine at cytosine-
phosphate-guanine (CpG) dinucleotide in the DNA by addition 
or removal of a methyl group. DNA methylation plays an integral 
role in the regulation of gene expression and genomic stability, 
disruption of which can lead to neoplastic transformation, car-
cinogenesis, and cancer progression (4). The relative stability of 
the DNA molecule together with the genome-wide distribution 
of DNA methylation marks has made it an attractive target for 
disease biomarker discovery (5). DNA methylation has proven to 
possess a great potential in the prediction of many human traits 
and conditions, including age, postpartum depression, childhood 
stress exposure, tumor class, response to therapy, and cancer 
progression/metastasis (5).
Epigenetic changes have been previously demonstrated in 
multiple cancers including PCa (6), with epigenomic signatures 
of PCa being proposed to be used as both diagnostic and prog-
nostic markers (3, 7). PCa-associated DNA methylation changes 
have also been found in the urine and serum of patients, raising 
hopes for non-invasive methods of PCa screening (3). These 
methylation changes have been found in various genes involved 
in hormonal response, cell-cycle regulation, cell invasion, and 
DNA damage repair (6). In particular, hypermethylation in the 
promoters of tumor suppressor genes APC, RARβ, and GSTP1, 
has been proposed to be used as a diagnostic marker for PCa 
(8). However, these assays have not generated optimal perfor-
mances, partly because they target selected candidate genes 
instead of markers discovered in a genome-wide search. The 
number of studies attempting to produce a diagnostic methyla-
tion algorithm for PCa using a genome-wide approach is lim-
ited. Furthermore, few studies have conducted a comprehensive 
genome-wide DNA methylation analysis to reveal the role of 
DNA methylation in PCa (3).
In the present study, we have conducted a genome-wide DNA 
methylation analysis to describe the DNA methylation changes 
in PCa. We have investigated potential mechanisms by which 
differentially methylated genes may be involved in the develop-
ment of PCa, by examining pathway enrichment and protein 
interactions. In addition, we have addressed mechanisms that 
regulate the establishment of differentially methylated regions 
(DMRs) in PCa by investigating the transcription factor (TF)-
binding patterns nearby the identified segments. Also, we report 
the copy number variations (CNVs) recurrently happening in 
PCa and evaluate their associations with the methylation levels of 
the overlapping DMRs. Finally, using the most differentiating 
CpGs, we have generated a classification model to distinguish 
the tumors from the adjacent benign tissues, and have validated 
this algorithm using a large independent cohort of benign and 
tumor prostate samples.
MaTerials anD MeThODs
specimen collection
Archival formalin-fixed paraffin-embedded tissues were col-
lected from the Department of Pathology at McMaster University, 
ON, Canada. The slides were reviewed by a pathologist to identify 
representative tumor tissue blocks. Enrichment of tumor cells 
was performed by tissue macro-dissection of predetermined 
areas, as outlined by Haemotoxylin and Eosin staining. Seven-
micron thick sections in isolated areas of interest with at least 
50% tumor cellularity were dissected to be used as tumor samples. 
Normal prostate samples were obtained from the adjacent tissues 
demonstrating no tumor involvement.
Methylation assay and Quality 
assessment
Genomic DNA extraction was conducted using the Illumina 
FFPE DNA recovery kit. Following bisulfite conversion, DNA 
methylation analysis of the samples was performed using the 
Illumina Infinium methylation 450 k bead chip array (San Diego, 
CA, USA), according to the manufacturer’s protocol. Both 
tumor and normal samples were assayed in one experiment to 
avoid batch effect. The resulting methylated and unmethylated 
signal intensity data were imported into R 3.4.2 for analysis. 
Normalization was performed using Illumina normalization 
method with background correction using the minfi package (9). 
Probes with detection p-value > 0.01, and those known to contain 
single nucleotide polymorphisms at the CpG interrogation or 
single nucleotide extension were removed. All of the samples 
were examined for genome-wide methylation density, and those 
deviating from a bimodal distribution were excluded. Factor 
analysis using multiple dimensional scaling did not reveal any 
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unexplained variation or outliers among the samples. The raw 
and processed genome-wide methylation microarray data has 
been deposited to gene expression omnibus (GEO) (accession 
ID: GSE112047).
identification of a Pca-related 
Methylation Profile
DNA methylation analysis was performed using a modifica-
tion of our previously published protocol (10–15). Methylation 
level for each probe was measured as a beta value, calculated 
from the ratio of the methylated signals vs. the total sum of 
unmethylated and methylated signals, ranging between 0 
(no methylation) and 1 (full methylation). This value was used 
for biological interpretation and visualization. For statistical 
analysis, beta values were logit transformed to M-values 
using the following equation: log2 (beta/1 −  beta). A linear 
regression modeling using the limma package (16) was used 
to identify the differentially methylated probes by testing the 
association of every CpG site with the level of tumor involve-
ment (0–90%). The generated p-values were moderated using 
the eBayes function in the limma package and were corrected 
for multiple testing using Bonferroni method. Probes with a 
corrected p-value < 0.01 and a methylation difference > 20% 
were considered significant. The effect size cut-off (20%) 
was determined following the examination of the volcano 
plot of the analysis, as conducted in our previous study (17). 
The identified probes were examined using an unsupervised 
hierarchical clustering to ensure their ability in separating the 
tumors from normal samples.
gene enrichment analysis and 
identification of Differential Methylation 
interaction hotspots
To identify the gene ontology (GO) terms overrepresented in 
the genes harboring differentially methylated probes, a gene-set 
enrichment analysis was performed using the missMethyl pack-
age (18), taking into account the number of CpG sites per gene. 
GO terms with a Bonferroni corrected p-value <0.01 were con-
sidered significant. Only the biological processes were reported. 
The redundant GO terms were reduced, and following a multiple 
dimensional scaling, visualized using REViGO tool (19). The 
relationships across the significant GO terms were plotted in a 
hierarchical order using GORILLA tool (20).
We used EpiMod algorithm (21) to search for the “interactome 
hotspots” of differential promoter methylation. In this algorithm, 
protein expression changes are inferred according to a model 
of inverse association between the promoter methylation and 
gene expression. Among the differentially expressed genes in an 
interactive network, a hotspot [or epigenetic module (EpiMods)] 
is a sub-network with an exceptionally large average edge-weight 
density (combined methylation statistics of the neighboring 
genes) as compared to the rest of the network (21). To assign 
a statistical significance to the identified hotspots, 1,000 Monte 
Carlo randomization of the molecular profiles were conducted 
as suggested by the algorithm. Interactive network hotspots 
composed of at least ten genes and FDR < 0.01 were reported.
identification of DMrs in Pca
To identify genomic regions harboring methylation changes 
(DMRs), a bump-hunting approach was used by the bumphunter 
package (22). The analysis considered regions with >20% change 
in the overall methylation between tumor and normal samples 
with gaps no more than 500  bp among neighboring CpGs. As 
suggested by the package, 1,000 bootstrapping procedures were 
performed to compute family-wise error rate (FWER). We 
selected regions containing a minimum of three consecutive 
probes and FWER < 0.01. The identified regions were mapped 
to CpG islands and coding genes. Gviz package was used for 
visualization of the DMRs.
identification of copy number changes 
Using Dna Methylation array
To estimate the copy number alterations in the prostate tumor 
from the Infinium methylation array, the raw methylated and 
unmethylated intensities from every sample were summed, and 
quantile normalized using the preprocessCore package (23). The 
normalized matrix values were divided by the median values of 
every probe across the normal samples. The divided ratios were 
then log10 transformed, smoothed, and segmented using the 
DNAcopy Bioconductor package (24) to identify genomic regions 
in every sample showing a copy number change. A p-value of 
<0.01 obtained from 10,000 permutations was used to define a 
change point during segmentation. The segmented regions with 
a minimum of five probes and an average log ratio > 0.2 or <−0.3 
(corresponding to at least one copy amplification/deletion) were 
selected. Using the GenomicRanges package (25), the segments 
with a similar pattern of copy number change in both normal 
and tumor samples were excluded. Segments on chromosome 
six, overlapping HLA genes, were not considered due to normal 
variations in their copy numbers. From the remaining segments, 
those occurring in more than one tumor sample were reported.
TF-Binding site enrichment analysis  
in DMrs
We investigated the enrichment of TF-binding motifs in both 
the identified DMRs and their immediate surroundings (±5 kb) 
using the pipeline recommended by the RTFBSDB package (26). 
First, the entire direct and inferred Homo sapiens TF-binding 
motifs were downloaded from the Cis-BP database (27). Every 
DMR sequence and its ±5  kb surroundings were scanned for 
motif enrichment relative to a background genome of 100,000 
base pairs. As recommended by the package, the difference in 
the GC content of the DMRs and the background genome was 
accounted for by re-sampling of the background genome to avoid 
a potential bias due to GC content. The motifs with an enrich-
ment ratio ≥1.5 folds and a Bonferroni corrected p-value < 0.01 
were selected for assessment.
construction and Validation of a  
Dna Methylation-Based Diagnostic  
Model for Pca
The differentially methylated probes were used to build a clas-
sification model to differentiate tumor samples from the normal 
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tissues. Only CpG probes located outside the regions with 
copy number change were utilized for feature selection. First, 
a receiver operating characteristic curve analysis (ROC) was 
performed to identify the most differentiating probes. Those 
probes with an area under the curve (AUC) of 1.00 were retained. 
Next, pairwise correlations among the remaining probes were 
measured to identify and exclude the redundant features with 
R-squared >0.90. A least absolute shrinkage and selection opera-
tor (LASSO) was used to further narrow down the features and 
train the model, using the glmnet package (28). Following 1,000 
permutations, the shrinkage parameter of lambda with lowest 
misclassification error was selected and incorporated into the 
final model. The model was set to generate probability scores 
ranging 0–1, representing the chance of a given sample being 
a tumor. The default binary classifier’s probability threshold of 
0.5 was used as classification cut-off. To assess the performance 
of the model, publically available methylation data from normal 
and tumor prostate tissues, benign prostate hyperplasia (BPH), 
and samples of PCa metastasis in other tissues were downloaded 
from GEO and blindly supplied to the model. Based on the 
scores and classifications produced by the algorithm for these 
samples, we measured accuracy, sensitivity, specificity, and AUC 
as indices of performance for our classifier. The GEO accession 
IDs and their related publications of the methylation data files 
used for validation of our algorithm are mentioned here to 
give credit to the researchers providing these data. Tumor and 
adjacent benign array files were downloaded from GSE76938 
(29), GSE52955 (30), GSE47915 (31), GSE55479 (32), GSE83917 
(32), and GSE38240 (33). The normal prostate array data from 
radical prostatectomy due to bladder cancer, and those with BPH 
were obtained from GSE55599 (34). Methylation data of tissues 
with metastases from prostate were included in the files from 
GSE38240 (33).
ethics statement
This study has been approved by the Hamilton Integrated Research 
Ethics Board (#14-700-T). All of the samples and records were 
de-identified prior to analysis.
resUlTs
study cohort
The study cohort included 31 samples of archival prostate gland 
tissue with a confirmed diagnosis of prostate adenocarcinoma, 
assessed by a licensed pathologist. From 16 of these, adjacent 
normal tissues were collected to be used as the control group. 
The tumor sections were dissected ensuring a minimum of 50% 
cancer involvement using macrodissection. There was no overall 
difference between the age of the subjects in the control group 
(55.7 ± 7.3) and the tumor group (55.2 ± 9.9).
Pca generates a hypermethylation Profile
From a total of 440,532 CpG probes that passed the quality 
controls, a total of 6,167 were revealed to have a methylation 
difference of >20% between the two groups with a multiple 
testing corrected p-value <0.01 (Table S1 in Supplementary 
Material; Figure  1A). Out of these CpG sites, only 27 (0.4%) 
showed a hypomethylation change. The vast majority of these 
probes were annotated to a coding gene (n = 4,334, 70.2%). A 
significant number showed an association with regulatory fea-
tures, including 5,011 (81.2%) being located in or nearby a CpG 
island, 1,959 (31.7%) being annotated to DNase Hypersensitivity 
Sites, and 2,000 (32.3%) located in an enhancer element. Using 
an unsupervised hierarchical clustering, these probes were shown 
to be able to completely separate the two groups. The degree of 
hypermethylation was observed to be correlated with the level of 
tumor cellularity (Figure 1B). A correlation analysis between the 
mean methylation levels of the entire profile and tumor cellularity 
revealed a Pearson correlation coefficient of 0.92 (Figure S1 in 
Supplementary Material).
cell communication is the central 
Functional entity of Pca Methylation 
Profile
Gene-set enrichment analysis of the CpG sites with differential 
methylation identified 466 enriched GO terms (biological 
processes) with a multiple testing corrected p-value <  0.01, 
considering the number of probes in every gene (Table S2 in 
Supplementary Material). The most frequent terms in this list 
include various forms of cell–cell communications, growth, 
senescence, bone morphogenetic protein signaling, neurogen-
esis, and differentiation (Figure 2). Protein interaction analysis 
of the differentially methylated promoters using the EpiMod 
algorithm identified a total of 9 genes as a hotspot for protein–
protein interactions containing a minimum of 10 interacting 
partners and an FDR < 0.01 (Tables S3 and S4 in Supplementary 
Material; Figure S2 in Supplementary Material). Among these 
are genes known to be involved in carcinogenesis, including 
C-X-C motif chemokine ligand 5 (CXCL5), estrogen-related 
receptor gamma (ESRRG), and sclerostin domain containing 1. 
The most active hotspot, however, was found for collagen 
type-3 alpha-1, located at the center of an interactive network 
of COL5A2, COL5A1, COL11A1, COL11A2, PCOLCE, and 
HTRA1, all being members of extracellular matrix regulation 
pathways (Table S4 in Supplementary Material; Figure S2 in 
Supplementary Material).
genomic regions Differentially Methylated 
(DMrs) in Pca
Using a bump hunting approach, we found 613 genomic coordi-
nates containing a minimum of three consecutive CpGs, an aver-
age regional methylation difference >0.2, and a FWER <  0.01 
(Table S5 in Supplementary Material). All of these regions were 
hypermethylated, and the vast majority was mapped to coding 
genes and CpG Islands. Among the largest and most differentially 
methylated segments are hypermethylation in the promoters 
of tumor suppressors (APC, 10 probes, 30%; KLK10, 4 probes, 
28%), genes involved in regulation of cellular senescence (HIF3A, 
8 probes, 31%), cell communication and adhesion [protocad-
herin (PCDH) gene cluster (n = 88), 3–9 probes, 21–36%], and 
genes regulating the growth including PDE4D (6 probes, 23%) 
and estrogen receptor-related gamma (ESRRG, 6 probes, 24%). 
FigUre 1 | Differentially methylated cytosine-phosphate-guanine (CpG) sites in prostate cancer: (a) volcano plot of the comparison between the tumors and benign 
samples: X-axis: methylation difference (mean tumor − mean normal); Y-axis: negative logarithmic scale of p-value; vertical dashed lines: methylation difference 
cut-off (0.2); horizontal line: p-value cut-off (0.01, Bonferroni-corrected). The significant probes are shown in red; (B) Heatmap of the tumors (columns, blue bar), and 
the adjacent benign tissues (columns, red bar) using 6,167 differentially methylated loci (rows): intensity of blue color corresponds to the methylation levels. Numbers 
bellow columns: level of tumor cellularity.
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In addition, a number of chromatin regulators such as histone 
deacetylase 9 (HDAC9, 6 probes, 26%) and TET1 (4 probes, 31%), 
as well as genes coding for histone subunits (HIST1H-1A, 3G, 
4D, and 4F) were found to show increased methylation in their 
promoters (3–7 probes, 22–27%).
copy number changes (cnVs) in  
Pca correlate With DMr status
Copy number analysis identified a total of 33 segments in the 
tumor samples containing a minimum of five markers and one 
copy of loss/gain, observed in more than one tumor (Table S6 
in Supplementary Material). Most of these regions were located 
nearby coding genes. Out of these, two segments, one in chr2: 
29338077–29338258 and the other in chr15: 45421860–45422325, 
annotating to CLIP4 and DUOX1, were most recurrently ampli-
fied among the tumors (in seven and eight samples, respectively). 
Comparison of the CNV and DMR lists revealed that both of 
these regions also show an increased level of methylation (Table 
S5 in Supplementary Material; Figure 3). The same incidence was 
also observed for regions in the promoters of KRT3 and PLEC 
(each amplified in three tumors), but not among other CNVs. 
For instance, a segment in the promoter of PNCK (amplified in 
three tumors) did not reveal any hypermethylation change. These 
results suggested that the hypermethylation pattern seen in some 
of the DMRs might be associated with their CNV status.
DMrs in Pca are surrounded by Tumor 
suppressor-Binding Motifs
Analysis of 1,946 Homo-sapiens-specific TF-binding motifs from 
the Cis-BP database revealed that the DMR sequences rarely 
bind to any of these TFs. Similarly, a TF-binding site enrichment 
analysis found an inverse enrichment for any of these motifs 
among these DMR sequences (enrichment ratios < 1, data not 
shown). We hypothesized that this might be related to the pos-
sibility that DMRs are not a direct target for regulatory elements; 
rather, they occur as a result of cis-regulation by TFs binding to 
the sites around them. Therefore, we expanded the DMRs by 
5  kb upstream and downstream and re-analyzed the data. We 
found enrichment for 25 motifs specific to 18 TFs (minimum 
fold change: 1.5, Bonferroni corrected p-value < 0.01, Figure 4). 
Except for few being chromatin regulators (CGBP, MBD2, and 
DNMT1), all of these TFs were found to have tumor suppressor 
functionality (BRCA1, E2F1&2&5&7, EGR1-4, FLI1, NRF1, 
TFDP2, and STAT1), or indirectly mediate the suppression of 
tumorigenesis and tumor suppressor activity (SP4 and ZBTB33).
a Four-cpg classification Model  
enables accurate Diagnosis of Pca
To design a classification model with the ability of detecting PCa 
tumor status from methylation profile, we first performed feature 
selection from the significant PCa-related probes and then trained 
FigUre 2 | Gene-set enrichment analysis of differentially methylated cytosine-phosphate-guanine sites (CpGs) in prostate cancer: (a) multiple dimensional scaling 
of the gene ontology (GO) terms (circles): GO terms with closely related functionalities are clustered in groups. Circles with smaller distance from each other 
represent GO terms with similar functionality. The uniqueness of every GO term is shown using a color scale from blue (less unique) to red (more unique). 
Representative non-redundant GO terms from every cluster are written next to the related circles. Only 350 of the GO terms were selected by REVIGO for reduction 
and visualization (maximum software limit); (B) hierarchical relationship between the significant GO terms: the level of significance (p-value) of every functional 
category is illustrated by a color scale from white to blue.
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a LASSO model with a binary outcome (tumor vs. normal). To 
avoid a potential bias from the variations in DNA copy numbers, 
we excluded the probes located in CNV regions. Next, we selected 
the non-redundant and fully differentiating probes (AUC = 1.00), 
which resulted in the retention of 46 CpGs. These probes were 
incorporated into a LASSO model, which following penalization, 
assigned coefficients equal to 0 to 42 of the probes, dropping them 
out of the model. Therefore, the final model was trained using 
four CpGs (Figure  5A) on 16 normal samples and 31 tumors 
(model details in Table S7 in Supplementary Material). These four 
CpGs are located in the first intron of OLFM1, promoter of RFX7, 
12th intron of PTPRN2, and the promoter of FLOT1, respectively 
(Table S7 in Supplementary Material).
To test the model, we first assessed its performance on the 
training data. As expected, all of the samples were assigned a 
correct classification of tumor vs. benign (accuracy, sensitivity, 
specificity, and AUC of 100%; Figure  5B). Next, to validate 
our algorithm, we downloaded DNA methylation array data 
of prostate samples publically available from GEO, and blindly 
supplied their methylation levels from the four CpGs to our 
model for classification. Of a total of 234 tumor and 76 benign 
prostate arrays (adjacent tissue to tumor) that we found in GEO, 
the algorithm correctly classified 225 as having a tumor profile 
and 74 as being benign, respectively. Next, we downloaded six 
normal prostate arrays from radical prostatectomy due to blad-
der cancer and ten arrays from BPH samples and supplied them 
to our model, all of which were classified as normal, suggesting 
that our algorithm can also differentiate BPH from the tumor 
(Figure  5C). Altogether, this analysis revealed a sensitivity of 
0.96 (9 false negatives in 234 tumors), specificity of 0.98 (2 false 
positives among 74 adjacent benign, 6 BPH, and 10 normal), 
an overall accuracy of 0.97, and AUC of 0.98 for the validating 
dataset (Figure 5B). Among other files available from GEO were 
arrays from bone (n = 3), lymph node (n = 2), and soft tissue 
(n = 1) with metastases from PCa, all of which were confidently 
predicted to have a methylation profile similar to PCa. In addi-
tion, a total of 61 technical replicates of the prostate tumors were 
available from datasets GSE83917 and GSE55479. Prediction 
scores generated for these files remained consistent with their 
original pairs, including the false negatives, suggesting that our 
model is not sensitive to technical variation. The prediction 
scores for all of the above array files are presented in Figure 5C 
and Tables S8 and S9 in Supplementary Material.
DiscUssiOn
In this report, we have described DNA methylation changes in 
PCa as compared to the adjacent benign tissue and reported a 
hypermethylation profile, which is overrepresented in genes and 
interactive networks that regulate cell–cell signaling, cell com-
munications, growth, and differentiation. Our study has revealed 
that the DMRs in PCa do not directly overlap regulatory ele-
ments; instead, they are surrounded by TF binding motifs specific 
to tumor suppressors. And finally, we have demonstrated that by 
using as few as four CpGs one can accurately classify prostate 
specimens as malignant or benign.
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FigUre 3 | Continued
insights into the involvement of Dna 
Methylation in Pca
A hypermethylation profile has been reported by previous DNA 
methylation studies of PCa, which appears to be maintained in 
all stages of the disease, likely due to selection pressure (29, 35). 
Previous reports have also found that, in contrast to the 
hypermethylated CpGs that will gain further methylation dur-
ing tumor progression, hypomethylation events are less likely 
FigUre 4 | Motifs enriched within ±5 kb of differentially methylated regions: TF, transcription factor; N. Pos.: number of observed motifs; expected: number of 
expected motifs; enrichment: fold enrichment; p-value is corrected for multiple testing using Bonferroni method. Motifs are sorted by fold enrichment.
FigUre 3 | Correlation between copy number variation (CNV) status and DNA methylation in prostate cancer: hypermethylation in the promoter of the CLIP4 
gene partially correlates with its CNV status. The figure illustrates a segment in the promoter of CLIP4 gene, located in the short arm of chromosome 2. The 
region is marked with high levels of acetylation of the 27th lysine residue of Histone 3, (H3K27Ac), a maker associated with active promoters. The segment is 
also recognized as a cytosine-phosphate-guanine (CpG) island (green pane). Panels (a,B) represent 181 base-pairs of this segment, harboring a total of 8 CpG 
probes, which were identified to concurrently show both hypermethylation and CNV amplification. (a) The color scale of the vertical bars (each probe) 
represents the log ratios of the copy numbers. The color scale above 0.2 is shown with red and indicates a minimum of one copy amplification for the region. 
Color scales of white and light blue represent no CNV change (we defined a CNV loss with a log ratio less than −0.3, which is not observed for this region). 
Samples are sorted from top to bottom. The top 16 samples represent normal tissues and the lower samples indicate the tumors (vertical pane as an indicator: 
blue and pink). Within this segment, the right five probes show CNV amplification in tumors, but not in the adjacent benign tissues. (B) The methylation status 
of the same eight probes shows a hypermethylation in tumors (pink) relative to normal adjacent benign tissues (blue). Methylation level of every probe from 
every sample is presented with a dot, representing a methylation range between 0 and 1 (bottom to top). Lines represent mean, and shadows around the lines 
indicate 95% confidence intervals of the mean in every group. The region with CNV amplification is significantly hypermethylated; however, this 
hypermethylation extends beyond the CNV to three probes in the upstream.
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FigUre 5 | Prediction algorithm for classification of prostate samples: (a) four cytosine-phosphate-guanine (CpG) probes selected by LASSO for training the 
classification model show significant hypermethylation in the tumors as compared to the normal samples. Y-axis represents the methylation levels. (B) The 
classification model yields 100% accuracy [area under the curve (AUC) = 1.00] in the training dataset and 97% accuracy (AUC = 0.98) in the validating dataset of 92 
benign samples and 234 tumors (model details in Tables S7 and S8 in Supplementary Material); (c) classification scores generated by the model for 16 normal 
samples in the training dataset (Benign T), 31 tumor samples in the training dataset (Tumor T), 76 benign tissue from validating dataset (Benign V), 234 tumors from 
validating dataset (Tumor V), 6 normal radical prostatectomy from validating dataset (Normal RP), 10 benign prostate hyperplasia (BPH) from validating dataset,  
6 prostate cancer metastasis from bone, lymph node, and soft tissue (Metastasis), as well as 61 tumor technical replicates are shown using violin-jitter plots. Y-axis 
represents the tumor probability scores (0–1), stratified by different classes on the X-axis. Violin-jitter plots show the density and distributions of the scores in every 
category. The normal samples mostly receive a score between 0.15 and 0.45, while the majority of the tumors are scored >0.65. The default cut-off of 0.5 (dashed 
line) is used for classification. Only two of the normal samples out of 92 received a score similar to other tumors, and only 9 misclassifications out of 234 have been 
made for tumors. Technical replicates have also generated comparable scores to the samples in the original experiment.
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to be maintained in the more advanced stages of the disease 
(33). Consistent with these results, we observed that the level 
of hypermethylation in PCa directly correlates with the degree 
of tumor cellularity in the primary prostate specimens (Figure 
S1 in Supplementary Material). The postulated link between a 
hypermethylation profile and cancer is a model of translational 
silencing of tumor suppressors by promoter hypermethylation 
(6). Indeed, we have observed increased methylation in the pro-
moters of several tumor suppressor genes including APC (Figure 
S3 in Supplementary Material), a well-characterized tumor sup-
pressor gene associated with familial adenomatous polyposis, and 
KLK10, which has been shown to repress proliferation and induce 
apoptosis in PCa cells (36). Among other DMRs in genes involved 
in growth and differentiation in our study are PDE4D, encoding 
a signal transduction molecule with cyclic-AMP phosphodies-
terase activity that is shown in mice to promote proliferation of 
PCa (37). As well, we have observed promoter hypermethylation 
in ESRRG, which was also found to act as a hotspot for protein– 
protein interactions. Downregulation of ESRRG has been found 
in certain types of prostate carcinomas, and it has been shown 
that its increased expression can repress tumor proliferation 
regardless of androgen sensitivity (38).
Besides tumor suppressors with a potential role in cell 
growth and proliferation, analyses of gene-set enrichment 
and protein–protein interaction hotspots have revealed that 
methylation changes in PCa encompass a combination of bio-
logical processes extending beyond the regulation of growth 
to neurogenesis and cell–cell communication. The best-known 
involvement of neurons in cancer is perineural invasions, 
where tumor invades the neural tissue. Another form of 
neural involvement in cancer, namely neurogenesis, has been 
recently reported in prostate tumors as the formation of neural 
components, axonogenesis, and increased number of neurons 
(39). Neurogenesis has been found to correlate with both peri-
neural invasions and poor clinical outcomes in PCa (39). Our 
gene enrichment analysis contains multiple GO terms related 
to the development of the nervous system, including brain 
development, axonogenesis, and neurogenesis. In parallel, 
these analyses provide evidence for the involvement of diverse 
forms of cell–cell signaling and communications, ranging from 
regulation of the extracellular matrix to chemotaxis and cellular 
response to stimuli. Among all of the genes in our results that 
are known to take part in these processes, the PCDH genes 
are mutually involved in both neurogenesis and cell–cell com-
munications. Our DMRs contain extensive regions that overlap 
the promoters of close to 90 PCDH gamma genes and isoforms. 
Various members of this cluster have been shown to be present 
in cell–cell adhesion, neural stroma and synapses (40), and 
homophilic trans-interactions (41). Overexpression of PCDHs 
in vitro has been demonstrated to suppress Wnt signaling and to 
inhibit colony formations of cancer cells (42). Limited data sug-
gest an involvement of PCDH 8, 11, and PC in PCa; however, no 
information is available regarding the PCDH gamma genes in 
PCa (43–45). Hypermethylation of various subtypes of PCDH 
gamma promoter is reported in Wilms’ tumor, colorectal car-
cinoma, uterine leiomyosarcoma, esophageal adenocarcinoma, 
and Barrett’s esophagus (46).
Overall, the major biological mechanisms that can be inferred 
from the methylation changes in this study represent the driver 
events, required for the maintenance, integrity, and survival of the 
tumor rather than those that may initiate tumorigenesis resulting 
from the loss of tumor suppressor functions. Similarly, the most 
recurrent CNV changes in tumors were found as amplifications 
in the promoters of DUOX1, a NADPH oxidase involved in 
the maintenance of tissue homeostasis (47), as well as CLIP4, 
an intracellular linker protein whose knock-down has been 
shown to increase cell migration and viability in clear cell renal 
cell carcinomas (48). These two segments were also found to be 
hypermethylated, potentially by the expansion of the CG repeats 
or methylation quantitative trait loci resulting from CNV ampli-
fication (4). Therefore, some of the hypermethylation changes 
we have observed in PCa might be related to the CNV status of 
the regions. However, the more common phenomenon that is 
potentially involved in the establishment of the DMRs appears to 
be a dysregulation following a change in tumor suppressor activ-
ity. The interesting finding that almost the entire enriched motifs 
nearby DMRs are specific to tumor suppressors indicates that 
DMRs in PCa, which mainly represent cancer driver events, are 
potentially generated or maintained secondary to a dysregulation 
in tumor suppressors’ function.
clinical implications of the 4-cpg 
classification Model
The current method widely in use for the diagnosis of PCa is an 
8–12 core needle biopsy, which is well known to encompass a 
high false-negative rate (49). A significant number of cancer-free 
reports of the prostate biopsies are shown to be at risk of having an 
undiagnosed PCa (49). Approximately 25–50% of these men are 
diagnosed with PCa in a second biopsy performed within 1 year 
(50). On the other hand, a positive needle biopsy is not confidently 
replicable. Serefoglu et al. have shown that a repeat PCa diagnosis 
can be made only in 67.8% of biopsies from post-operative prostate 
glands of men undergone radical prostatectomy due to PCa, using 
the same 12-core mapping as performed pre-operatively (51). The 
main reason for this discrepancy is the spatiotemporal, molecular, 
and morphological heterogeneity of the prostate adenocarcinoma 
that leads to a non-uniform presentation of the tumor by the 
involved tissue (52). This indicates that a significant portion of 
negative biopsies can contain molecular changes associated with 
cancer without completely representing histological features of 
adenocarcinoma (53, 54), and thus a reliable biological marker 
would assign a diagnosis to a considerable number of suspicious 
samples undiagnosed following histopathology examination. 
Consistent with this, Troyer et  al. was among the first to pub-
lish a report that DNA methylation markers can detect PCa in 
histopathologically cancer-negative prostate tissues of men who 
went on to have subsequently positive biopsies (55). Within a 
few years of this report, methylation markers in the promoters 
of GSTP1, APC, and RASSF1 were introduced as a commercial 
tissue-based assay to identify patients in need of repeat biopsies 
(56). However, clinical validation studies of this assay have only 
revealed a sensitivity of 68% and a specificity of 64% (57, 58), 
questioning the reliability of a candidate gene approach in PCa 
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screening. We have also observed hypermethylation to a variable 
extent in all these three genes (Tables S1 and S5 in Supplementary 
Material); however, this is not consistently found across all speci-
mens (Figure S3 in Supplementary Material for APC), thereby 
resulting in reduced sensitivity for cancer tissue specification. As 
a consequence, efforts to identify DNA methylation biomarkers 
shifted toward a genome-wide approach for PCa. Goh et  al. 
(59), following a genome-wide DNA methylation analysis, have 
proposed a 55-CpG classification model, which has yielded 89.8% 
sensitivity and 66.7% specificity in the validation step. More 
recently, Kirby et al. have reported a 3-CpG model for classifica-
tion of tumor samples from the adjacent benign tissues, which 
reached a sensitivity of 90% and specificity of 82% as measured 
in a validation cohort of 49 benign and 213 tumor samples (29).
Here, we have further improved the classification of prostate 
samples by designing a 4-CpG classification model, which has 
revealed 100% accuracy in separating tumors from benign tissue 
in our internal dataset. The validation of this model using hetero-
geneous cohorts of 326 prostate samples from publically available 
resources has revealed 96% sensitivity and 98% specificity with 
an overall accuracy of 97% (AUC = 0.98). To our knowledge, this 
far supersedes performance of any reported DNA methylation-
based algorithm for the diagnosis of PCa. Our model is sensitive 
enough to detect PCa metastasis in other tissues, including bone, 
soft tissue, and lymph nodes (Figure 5), while it is still specific 
enough to discriminate BPH from the tumor. This method can 
be used to develop a low-cost high-throughput targeted assay for 
diagnosis of PCa or to complement the pathological examina-
tion of cancer-negative needle biopsies. It may also be used for 
confirmation of metastatic lesions outside of the prostate.
Future Directions
The current classification algorithm presented in this study is 
designed and validated using tumor samples and normal adjacent 
tissues obtained from radical prostatectomy. Before this method 
is translated into clinical use, further computational training, 
validation, and clinical trials are required. First, the performance 
of the model needs to be assessed on samples with diverse ranges 
of tumor cellularity. In the present study, we did not assess samples 
with tumor involvement less than 50%, and thus, the accuracy 
remains unknown with regards to samples with lower levels of 
tumor cellularity. In a small subset of the tumor samples in the 
validation dataset, we observed scores close to the ones found in 
normal tissues, which might be caused by a potentially low level 
of tumor cellularity in them. Computationally, we can re-train 
the algorithm to enable the prediction of tumor cellularity as a 
continuous measure. In addition, the model will have to be tested 
and potentially re-trained on DNA obtained from needle core 
biopsies. In order to make this technology more broadly applicable, 
its accuracy should be demonstrated on limited amounts of DNA 
obtained from needle biopsy specimens, and address whether the 
performance is similar across the biopsy specimens and the entire 
prostate gland. Another important aspect to assess is whether 
this assay can detect neoplastic transformation in specimens that 
appear to be normal in an initial pathological examination, but 
are demonstrated to harbor tumor in subsequent assessments of 
the same core (i.e., false negatives).
The markers and methodology presented here could be 
expanded to research applications with the aim of developing 
novel approaches in the non-invasive screening of PCa using 
circulating tumor DNA. The study we have described herein 
reveals the power of high-throughput genomic technologies, 
in combination with machine learning, to increase our under-
standing of the biology of cancer and, at the same time, to 
provide us with novel, precise approaches for cancer screening 
and diagnosis.
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